Serum-free culture medium and IL-7 costimulation increase the sensitivity of ELISpot detection. by Martinuzzi, Emanuela et al.
Serum-free culture medium and IL-7 costimulation
increase the sensitivity of ELISpot detection.
Emanuela Martinuzzi, Matthieu Scotto, Emmanuelle Ene´e, Vedran Brezar,
Jean-Antoine Ribeil, Peter Van Endert, Roberto Mallone
To cite this version:
Emanuela Martinuzzi, Matthieu Scotto, Emmanuelle Ene´e, Vedran Brezar, Jean-Antoine
Ribeil, et al.. Serum-free culture medium and IL-7 costimulation increase the sensitivity of




Submitted on 26 Mar 2008
HAL is a multi-disciplinary open access
archive for the deposit and dissemination of sci-
entific research documents, whether they are pub-
lished or not. The documents may come from
teaching and research institutions in France or
abroad, or from public or private research centers.
L’archive ouverte pluridisciplinaire HAL, est
destine´e au de´poˆt et a` la diffusion de documents
scientifiques de niveau recherche, publie´s ou non,
e´manant des e´tablissements d’enseignement et de
recherche franc¸ais ou e´trangers, des laboratoires
publics ou prive´s.
1SERUM-FREE CULTURE MEDIUM AND IL-7 COSTIMULATION
INCREASE THE SENSITIVITY OF ELISPOT DETECTION
Emanuela Martinuzzia,b, Matthieu Scottoa,b, Emmanuelle Énéea,b, Vedran Brezar a,b, Jean-
Antoine Ribeilc, Peter van Enderta,b and Roberto Mallonea,b,*
aINSERM, U580, Necker Hospital, Paris, France; bUniversité Paris Descartes, Faculté de 
Médecine René Descartes, Paris, France; cDépartement de Biothérapie, Necker Hospital, 
Paris, France.
*Corresponding author, INSERM U580, Bâtiment Sèvres, Hôpital Necker, 161 rue de Sèvres, 
75743 Paris Cedex 15, France. Tel.: +33 1 4449 5378; fax: +33 1 4449 5382
E-mail address: mallone@necker.fr  (R. Mallone).
Abbreviations: ANOVA, analysis of variance; CMV, cytomegalovirus; EBV, Epstein-Barr 
virus; GAD, glutamic acid decarboxylase; HS, human serum; IA-2, insulinoma-associated 
protein 2; IGRP, islet glucose-6-phosphatase catalytic subunit related protein; MP, matrix 




anuscript    inserm
-00266553, version 1
HAL author manuscript
Journal of immunological methods 2008;:epub ahead of print
2ABSTRACT
The identification of parameters maximizing detection sensitivity in ELISpot assays is 
important to transfer this technology into the clinical setting for identifying rare Ag-specific 
CD8+ T cells. We have therefore considered human IFN-CD8+ T cell responses against viral 
epitopes to analyze different variables which could be critical during the epitope-specific
stimulation period. Two parameters were found to greatly enhance detection sensitivity (i.e., 
to specifically increase epitope-driven signal while keeping background noise to a minimum): 
use of human serum-free vs. serum-supplemented culture medium (2.4-fold median increase) 
and addition of low dose IL-7 (1.5-fold increase). Incorporating both of these parameters into 
the ELISpot procedure proved capable of greatly amplifying (35.1-fold increase) the low 
grade CD8+ T cell responses directed against -cell epitopes of type 1 diabetes patients, as 
compared to a previously optimized procedure using human serum-supplemented medium 
and low dose IL-2. Implementation of this ELISpot procedure should expedite development 
of “immune staging” protocols for autoimmune as well as tumor and infectious diseases.        
Key words: autoimmunity, memory, monitoring, T cells, type 1 diabetes
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31. Introduction
Detection and quantification of antigen-specific T cell responses has represented a milestone 
advance in the immunology field. Not only it has allowed to address fundamental questions
about the dynamics of T cell responses, but it has also offered key clinical applications for 
infectious, tumoral and autoimmune diseases.
Of the two T cell arms of adaptive immunity, CD8+ T cells have received more attention due 
to their well established role in mounting immune responses against viral and cancerous 
threats. Not denying the contribution of CD4+ T cells in these settings (Perez-Diez et al., 
2007), progress with their study has lagged behind due to several technical limitations, 
including more scattered HLA Class II distribution (Nepom, 1995), more difficult epitope 
identification (Kwok et al., 2001), troublesome HLA Class II tetramer production (Mallone 
and Nepom, 2004) and lower Ag-specific T cell frequencies (Homann et al., 2001). 
Furthermore, more recent studies in type 1 diabetes (T1D) (Amrani et al., 2000;Toma et al., 
2005;Mallone et al., 2007) and multiple sclerosis (Crawford et al., 2004) have highlighted the 
fundamental contribution of CD8+ T cells in autoimmunity (Liblau et al., 2002;Walter and 
Santamaria, 2005), thus challenging the paradigm depicting these diseases as predominantly 
CD4+ T helper 1–mediated. 
Among the various techniques which can be used to detect CD8+ T cell responses, two main 
strategies share the mainstream. On one side, flow cytometry-based technique allow for direct 
visualization of Ag-specific cells by a variety of structural (i.e., peptide-HLA tetramer 
binding) or functional (e.g, IFN-  secretion, CD107a/b upregulation) readouts (Kern et al., 
2005). On the other side, ELISpot-based techniques give an indirect detection of Ag-specific 
T cells by means of their cytokine (mostly IFN-	

	
at least a 
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410-fold higher sensitivity, as they can detect as few as 0.001% Ag-specific cells (Meierhoff et 
al., 2002).
The detection sensitivity reached by ELISpot is particularly useful in the autoimmune context, 
since autoreactive T cell responses are typically of much lower grade (i.e., lower intensity and 
precursor frequency) than those found in the viral and tumor setting (Mallone and Nepom, 
2005). For example, our recent ELISpot studies on T1D patients vs. healthy controls indicate 
that the -cell epitope-specific CD8+ T cell fractions which can be measured in peripheral 
blood are in the order of 0.004% of total PBMCs (Mallone et al., 2007). Optimization of 
current ELISpot protocols is therefore highly needed to maximize the chances of detecting 
such rare events and to eventually reach clinical application. Such optimization should aim at 
obtaining the highest specific signal, while keeping the background noise of the system to a 
minimum. We here address this issue by considering different costimulatory parameters 
during the ELISpot culture incubation, in order to achieve preferential amplification of the 
epitope-specific T cell responses.         
2. Materials and methods
2.1. Study subjects
Eight HLA-A2+ (HLA-A*0201) healthy donors (Table I) were selected by FACS screening of 
lysed whole blood with the anti-HLA-A2 mAb BB7.2. Subsequent genotyping was performed 
using the Olerup SSP HLA*02 kit (GenoVision/Qiagen, Vienna, Austria). All subjects gave 
written informed consent and the study was approved by the Local Ethics Committee. PBMCs 
were isolated by density gradient centrifugation using lymphocyte separation medium (PAA, 
Les Mureaux, France), and immediately used or stored frozen (10% DMSO in pooled human 
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5male AB serum). In selected experiments, immunomagnetically CD4-depleted or CD8-
enriched (>90% pure) PBMCs were prepared using Miltenyi CD4 positive and CD8 negative 
selection kits, respectively (Miltenyi Biotech, Paris, France).
To test detection of -cell-specific CD8+ T cell responses in T1D vs. healthy subjects, PBMCs 
were obtained from three adult (29-, 40- and 63-yo) HLA-A2+ male patients with new onset 
T1D (1, 5 and 30 days after diagnosis, respectively) positive for anti-GAD antibodies. T1D 
diagnosis was formulated according to consensus criteria (American Diabetes Association, 
2006).
2.2. Peptides
The following HLA-A2-restricted viral peptides (>80% pure; Schafer-N, Copenhagen, 
Denmark) were used: Flu matrix protein (MP)58-66 (GILGFVFTL), cytomegalovirus (CMV)
pp65495-503 (NLVPMVATV) and Epstein-Barr virus (EBV) BMLF1280-288 (GLCTLVAML). 
Negative controls were HIV gag77-85 (SLYNTVATL) and DMSO diluent alone. A PHA 
positive control (1 μg/ml; Sigma, Lyon, France) was included in all experiments. The 
response of each subject to these peptides (Flu, CMV, EBV or a pool of the three) was titrated 
in preliminary experiments to identify a suboptimal concentration for each donor giving a 
positive response (> basal +3SD, see below), but with low numbers of epitope-specific spots 
(<100 spot-forming cells/106 PBMCs after basal subtraction). This suboptimal concentration 
was subsequently used in all experiments.
The immunodominant -cell epitopes proinsulin (PI)A12-20, glutamic acid decarboxylase 
(GAD)114-123, insulinoma-associated protein 2 (IA-2)206-214 and islet glucose-6-phosphatase 
catalytic subunit related protein (IGRP)265-273 were previously described (Mallone et al., 
2007;Blancou et al., 2007;Takaki et al., 2006).    
H
AL author m
anuscript    inserm
-00266553, version 1
62.3. mAbs, cytokines and culture media
Anti-CD28 mAb (clone CD28.2) was purchased from BD Pharmingen (Le Pont de Claix, 
France). Recombinant human IL-2 and IL-7 were from R&D Systems (Lille, France). RPMI, 
AIM-V (both from Invitrogen, Cergy Pontoise, France) or X-VIVO 15 culture medium
(BioWhittaker-Lonza, Levallois-Perret, France) were used for ELISpot assays, as specified 
for each experiment.
2.4. ELISpot
Ninety-six well PVDF plates (Millipore, Saint-Quentin-en-Yvelines, France) were coated 
overnight with an anti-IFN--CyTech, Utrecht, The Netherlands). After  blocking with 
RPMI + 10% human serum (HS; PAA) for 1 h at 37°C, peptides were distributed into wells at 
the suboptimal concentrations (0.5-500 nM) previously determined for each donor, along with 
the appropriate co-stimuli, as detailed for each experiment. PBMCs were seeded in triplicates 
at 3x105 cells/well and cultured for 20-24 h. Following PBMC removal, IFN- secretion was 
visualized with a biotin-conjugated anti-IFN- mAb (U-CyTech), alkaline phosphatase-
conjugated ExtrAvidin and Sigmafast 5-bromo-4-chloro-3-indolyl phosphate/nitro blue 
tetrazolium (BCIP/NBT) tablets (both from Sigma). Spots were counted using an AID reader 
(Strassberg, Germany), means of triplicate wells calculated and results expressed as spot-
forming cells (SFC)/106 PBMCs after background subtraction. The cut-off for a positive 
response was set at 3SD above the average basal reactivity (i.e., reactivity against HIV gag77-






-cell epitopes in T1D patients) and 
specificity (i.e., lowest number of positive responses in healthy controls), as determined by 
receiver-operator characteristics (ROC) analysis (Mallone et al., 2007). The variability of our 
ELISpot assay is of 14.1% intra-assay, 4.2% at the analytical inter-assay level (i.e., using 
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7thawed PBMC samples frozen on the same occasion) and 9.2% at the pre-analytical and 
analytical level (i.e., using separate blood draws from the same donor) (Mallone et al., 2007). 
Coefficients of variation between fresh and frozen samples are typically <10%.
2.5. Statistical analysis
All graphs are displayed as means of triplicate wells ±SEM. Since spot numbers are normally 
distributed within each triplicate, comparisons of means within the same donor were carried 
out with two-tailed Student's t test, while the non-parametric Wilcoxon matched pairs test was 
used for comparing two ELISpot conditions across the whole cohort of donors. Analysis of 
variance (ANOVA) was used for comparisons among multiple groups. P <0.05 was 
considered to be of statistical significance.
3. Results
3.1. Titration of epitope-specific responses
In order to better visualize the influence of different culture conditions on the ELISpot 
performance, we preliminarily titrated the reactivity of each donor to one viral epitope chosen
among Influenza, CMV or EBV ones, or to a pool of the three (Tab. I). We thus identified for 
each subject a suboptimal (0.5-500 nM) peptide concentration achieving a positive response 
but with no more than 100 SFC/106 PBMCs when tested without cytokine addition and in 
RPMI+ 10% HS (Fig. 1A). As we plate 3x105 PBMCs/well, this corresponds to <30 spots 
counted in each well before normalization to 106 PBMCs, a number which avoids counting 
inaccuracies due to excessive spot densities. All experiments (Fig. 1 to 5) were subsequently 
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83.2. Culture media
As differences in human serum (HS) batches may affect the reproducibility of the ELISpot 
technique, we first investigated whether substituting HS-supplemented RPMI with AIM-V
medium would improve assay performance. As shown in Fig. 1A, AIM-V performed 
consistently better than HS-supplemented RPMI, as all but one donor displayed increased 
responses with this latter culture condition. The median increase in specific signal was of 2.4-
fold (range 1 – 6.4-fold; P<0.03 by Wilcoxon test), while background noise was low in all 
instances (<15 SFC/106 PBMCs).
The lower specific signals obtained with HS-supplemented medium were not due to poor 
performance of the particular HS batch used, as different lots – either produced locally or 
commercially available – gave similar results (Fig. 1B). However, the absence or presence of 
HS did not account for the difference between AIM-V and RPMI-HS, as HS-supplemented 
and non-supplemented AIM-V did not differ significantly in their effect (Fig. 1C). A second 
HS-free synthetic medium (i.e., X-VIVO 15) gave similar results, i.e., it performed as well as 
AIM-V, better than HS-supplemented RPMI, and not differently with and without HS 
supplementation (Fig. 1C).
The AIM-V also performed better than HS when used as a freezing medium (10% 
DMSO/90% AIM-V or HS). At thawing, the specific signal did not differ significantly (not 
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93.3. Anti-CD28 costimulation
We next tested the effect of adding an anti-CD28 mAb to the ELISpot culture, as it has 
previously been reported that such costimulation increases detection sensitivity (Ott et al., 
2004). However, we did not observe any beneficial effect (Fig. 2): addition of anti-CD28 
mAb (1 μg/ml) to AIM-V medium marginally increased signal detection in only 1 of the 4 
donors tested (39.7% increase; P=0.29). This was moreover obtained at the expense of a 
much higher background. Even in those subjects where the specific signal was not improved, 
the increase in noise was quite important (median increase 7.3-fold; range 1 – 13.3; P<0.03 by 
Student’s t test for 3 of 4 donors).  
3.4. IL-2 costimulation
We have previously reported that addition of low dose (0.5 U/ml) IL-2 leads to a small but 
consistent improvement in ELISpot sensitivity, as assessed by measuring low grade CD8+ T 
cell responses against -cell autoantigens in T1D patients (Mallone et al., 2007;Blancou et al., 
2007). This was indeed still the case when HS-supplemented RPMI medium was enriched 
with low dose IL-2 as per our previous protocol to detect viral epitope-specific responses (Fig. 
3; median signal increase 2.3-fold, range 1.1 – 3.8; P<0.06 by Wilcoxon test). However, when 
this IL-2 supplement was added to the HS-free AIM-V medium, this improvement was no 
longer observed (Fig. 4). Rather, a marginal increase in specific signal (median 1.05-fold, 
range 0.52 – 1.4-fold; P=0.56) was counterbalanced by a larger increase in background noise 
(median 2.4-fold, range 0.83 – 3.6-fold; P=0.16). These increases were even more important 
when higher IL-2 doses where used. IL-2 doses lower than 0.5 U/ml did not induce any 
significant effect as compared to unsupplemented HS-free AIM-V (not shown). 
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As IL-7 is thought to be an important co-stimulation factor for memory T cells (Bielekova et 
al., 1999), we hypothesized that it could also have a more beneficial effect than IL-2 on the 
ELISpot-detected signal. Indeed, low dose (0.5 ng/ml) IL-7 induced a small yet highly 
reproducible increase in specific signal, while increasing the basal levels of reactivity only 
marginally (Fig. 5A). The median increase in net signal was of 50% (range 20 – 250%; 
P<0.03 by Wilcoxon test), while background noise was unaffected in most cases (median 
increase 0%, range -11 – 63.9%; P=0.31). Higher IL-7 doses (1-5 ng/ml) only gave a 
marginal increase in specific signal (median 21.7 and 7.6%, respectively; P=0.22 and 0.44), 
while the increase in background level was much higher (median 49.1 and 267.0%; P=0.06 
and 0.03). IL-7 supplements lower than 0.5 ng/ml did not have any effect as compared to
unsupplemented AIM-V (not shown). The effect of low dose IL-7 was exerted on CD8+ T 
cells, as it was still present when CD4-depleted PBMCs or purified CD8+ cells were used
(Fig. 5B).
3.6. IL-7-supplemented AIM-V medium allows for easier detection of low grade autoimmune 
CD8+ responses
Finally, we looked at whether this optimized protocol was suitable to detect the low grade 
CD8+ T cell responses which characterize autoimmune diseases such as T1D. Indeed, use of 
either AIM-V medium or of IL-7 costimulation increased the specific signal obtained upon 
challenging PBMCs from a T1D patient with the HLA-A2-restricted GAD114-123 epitope (Fig. 
6A). Interestingly, use of both AIM-V and IL-7 achieved a synergistic effect, with a 13-fold 
increase in signal as compared to HS-supplemented RPMI (P<0.04).
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HLA-A2+ T1D patients and healthy controls were subsequently compared for their responses 


-cell epitopes by using either our previously described protocol 
(HS-supplemented RPMI + IL-2) (Mallone et al., 2007) or the newly optimized condition 
with HS-free AIM-V and IL-7 (Fig. 6B). Such responses were detected in T1D but not in 
healthy subjects, as previously reported (Mallone et al., 2007). Some rise in the background 
levels was observed with IL-7-supplemented AIM-V in 4 of 6 cases, but it was overall not 
statistically significant (median increase 2.6-fold; range 0.34 – 13.0-fold; P=0.44 by 
Wilcoxon test). More importantly, this rise was outweighed by a much higher amplification of 

-cell epitope-specific responses in 4 of 4 cases (median increase 35.1-fold; range 3.6 –
162.2; P<0.001). Of these 4 responses, 3 which would have remained undetected with the IL-
2 protocol (being lower than the basal mean + 3SD cut-off) were instead ranked as positive 
with AIM-V + IL-7. Of note, this amplification effect was specific, as the -cell-directed
responses of healthy subjects did not rise significantly in 91.7% (11/12) of cases, and 
remained negative in all instances.
4. Discussion
We provide evidence that optimized culture and costimulation conditions during ELISpot 
incubation greatly improve epitope-specific stimulation. Small increases in background levels 
were outweighed by a much higher increase in specific signal. Two parameters were found to 
be critical: substitution of HS-supplemented RPMI with HS-free AIM-V medium; and 
addition of low dose (0.5 ng/ml) IL-7.
The higher efficacy of the AIM-V medium could have been due either to exclusion of HS 
from the culture condition or to the composition of the AIM-V medium itself. The former 
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hypothesis was excluded, as addition of HS to AIM-V or X-VIVO did not bring a significant
change. The latter hypothesis is therefore the most likely, but the proprietary formulation of 
AIM-V does not allow further speculations. However, excluding HS from the culture media 
brings the advantage of avoiding lot-to-lot variabilities.
The costimulatory effect of IL-7 was found to be quite selective on the epitope-specific 
fraction of interest, while only marginally increasing basal reactivity. Other cytokines 
previously found to increase detection sensitivity such as IL-15 (Jennes et al., 2002) did not 
have the same effect, as they greatly increased background noise, with little advantage on the 
net signal revealed (not shown). The advantage of IL-7 vs. IL-2 could be due to a preferential 
effect on the IL-7 receptor-positive (CD127+) effector/memory compartment as compared to 
the CD127- Treg subset (Liu et al., 2006;Seddiki et al., 2006). It has indeed been shown that 
exclusion of Treg cells from in vitro cultures eases detection of autoimmune responses for 
CD4+ T cells (Danke et al., 2004), and the same is likely to be true for CD8+ T cells (Piccirillo 
and Shevach, 2001). Alternatively, the IL-7 effect may be due to a preferential action on 
memory  vs. naïve T cells (Bielekova et al., 1999;Welch et al., 1989;Surh et al., 
2006;Melchionda et al., 2005;Tan et al., 2002). In a therapeutic perspective, it is this memory 
subset which contains the fraction of interest, i.e., T cells which have already encountered the 
Ag and are therefore more suitable to be boosted or quenched, depending on the clinical 
setting. Although the preferential action of IL-7 on memory vs. naïve T cells is a matter of 
debate (Bielekova et al., 1999;Tan et al., 2001), the preferential targeting of the memory 
compartment could be more effective for IL-7 than for IL-2 or anti-CD28 mAb. As naïve T 
cells are more dependent on costimulation (Viglietta et al., 2002) and in light of the 
importance of both CD28 and IL-2 signals for Treg biology (Tang et al., 2003), these two 
regimens may actually exert their effect in the opposite direction, preferentially boosting 
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naïve or Treg responses rather than memory/effector ones. Both hypotheses (i.e., preferential 
activation of effector/memory vs. regulatory T cells or of memory vs. naïve T cells) are open, 
as the IL-7 effect was maintained when CD4-depleted PBMCs or purified CD8+ T cells were 
used. 
Our observation that anti-CD28 costimulation did not have any beneficial effect on ELISpot 
detection sensitivity is at variance with the report of Ott et al., who reached opposite 
conclusions (Ott et al., 2004). This may be due to the different culture medium used (AIM-V 
in our study vs. HS-supplemented RPMI in the quoted report). It is possible that the richer 
composition of the AIM-V medium makes T cells more sensitive to further costimulation. 
This was indeed our observation with regard to IL-2, which was effective when added to HS-
supplemented RPMI (Fig. 3), but much less with HS-free AIM-V due to background increase 
(Fig. 4). The culture medium used should therefore be taken into account when titrating 
costimulatory reagents. Keeping the noise of the system to a minimum is particularly 
important when looking at low grade T cell responses, as small changes can easily remain 
undetected over a high background. 
The final advantage of this optimized stimulation scheme on the ELISpot detection sensitivity 
!
-cell epitope-specific CD8+ responses in T1D patients vs. healthy 
controls. While maintaining specificity with regard to disease status, IL-7-supplemented HS-




specific responses. Such an increase is unlikely to solely reflect an expansion of the epitope-
specific precursors, given the short (24 h) stimulation period. It probably also reflects
increased bystander activation, a mechanism with a much higher potential for amplifying T 
cell responses. It may be argued that such amplification does not anymore reflect the ex-vivo 
precursor frequency. However, the main scope of ELISpot techniques in the clinical setting –
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especially in the autoimmunity field – is to allow for disease monitoring, i.e., for early 
diagnosis, prognostic stratification and therapeutic follow-up (so called “immune staging”)
(Mallone and Nepom, 2005). Such clinical applications rely on sensitive and quantitative 
detection of the relevant T cell responses rather than on precise counting of the actual T cell 
frequencies. The proposed ELISpot procedures should greatly facilitate this task. 
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Table and Figure legends
Tab. I. HLA-A*0201+ healthy donors enrolled in the study. The viral epitope(s) and the 
suboptimal concentrations used for ELISpot testing (Fig. 1 to 5) are indicated.
Fig. 1. (A) Basal-subtracted epitope-specific responses obtained by ELISpot using either 
RPMI + 10% HS (left) or HS-free AIM-V (right) as culture medium. Basal reactivities 
(responses against an HIV gag77-85 control epitope and DMSO diluents alone) were <15 
SFC/106 PBMCs in all instances and did not differ significantly between the two culture 
conditions. *P<0.04 for the comparison between the two culture media by Student’s t test 
(P<0.03 when comparing cumulative data for all donors by Wilcoxon test). (B) Epitope-
specific responses measured by ELISpot using RPMI medium supplemented with different 
HS batches. The background-subtracted signal (grey bars) and the basal reactivity levels 
(white bars) are shown. Differences in background and in basal-subtracted signals among HS 
lots are not statistically significant, as assessed by ANOVA. HS 1 is the batch used for the 
experiments depicted in panel A and in all other experiments. Results refer to a representative 
experiment performed in duplicate. (C) Effect of different HS-free media and of HS 
supplementation on ELISpot responses. Two donors were tested with different media as 
indicated. *P<0.02 by Student’s t test (P<0.02 when comparing cumulative data for both 
donors by Wilcoxon test). **P<0.05 (P=0.11 for cumulative data). (D) Percent cell recovery 
upon thawing of PBMCs frozen either in 10% DMSO/90% HS (left) or 10% DMSO/90% 
AIM-V (right). **P<0.04 for the comparison between the two conditions. Results are means 
of three separate experiments.
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Fig. 2. Effect of anti-CD28 costimulation on the epitope-specific T cell responses measured 
by ELISpot. PBMCs from the indicated donors were tested using HS-free AIM-V medium 
with or without addition of anti-CD28 mAb (1 μg/ml). Grey bars represent the basal-
subtracted ELISpot signal, while the basal reactivity is shown in the superimposed white bar. 
Total bar height (grey plus white) therefore represents raw spot counts before basal 
subtraction. **P<0.03 for the comparison between noise levels of anti-CD28-stimulated vs. 
unstimulated conditions by Student’s t test. All differences in basal-subtracted ELISpot 
signals are not statistically significant.
Fig. 3. Effect of low dose (0.5 U/ml) IL-2 addition to HS-supplemented medium on ELISpot 
responses. PBMCs from different donors were subjected to ELISpot testing using RPMI + 
10% HS with (left) or without (right) IL-2. Basal-subtracted responses are shown, where 
background levels did not differ significantly between the two culture conditions. *P<0.03 for 
the comparison between the two conditions (P<0.06 when comparing cumulative data for all 
donors by Wilcoxon test).
Fig. 4. Effect of IL-2 addition to HS-free AIM-V medium on ELISpot responses. PBMCs 
from different donors were subjected to ELISpot testing using HS-free AIM-V without IL-2 
(black bars) or with 5, 1 or 0.5 U/ml IL-2 (dark grey, light grey and hatched bars, 
respectively). The superimposed white bars represent background reactivities for each 
condition, while total bar heights (colored plus white portion) correspond to raw spot counts 
before basal subtraction, as for Fig. 2. *P<0.02 for the difference in basal-subtracted 
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responses as compared to the “no cytokines” condition. **P<0.04 for the difference in 
background noise as compared to the “no cytokines” condition. 
Fig. 5. (A) Effect of IL-7 addition to HS-free AIM-V medium on ELISpot responses. PBMCs 
from different donors were subjected to ELISpot testing using HS-free AIM-V without IL-7 
(black bars) or with 5, 1 or 0.5 ng/ml IL-7 (dark grey, light grey and hatched bars, 
respectively). Data representation is the same as in Fig. 4. *P<0.04 for the difference in basal-
subtracted responses as compared to the “no cytokines” condition (P<0.03 for the IL-7 0.5 
ng/ml vs. “no cytokines” condition when comparing cumulative data for all donors by 
Wilcoxon test). **P<0.05 for the difference in background noise as compared to the “no 
cytokine” condition (P<0.05 for the IL-7 5 ng/ml and 1 ng/ml vs. “no cytokine” conditions 
when comparing cumulative data for all donors by Wilcoxon test). (B) Effect of low dose (0.5 
ng/ml) IL-7 addition on the ELISpot responses of CD4-depleted PBMCs and purified CD8+ T 
cells. A representative experiment out of two performed is shown.
Fig. 6. (A) Detection of GAD114-123-specific CD8+ T cell responses with different culture 
media with or without IL-7 supplementation. PBMCs from a T1D patient were tested with 
different ELISpot conditions as indicated. **P<0.04. (B) Comparison between IL-2-
supplemented RPMI and IL-7-supplemented AIM-V media for detecting low grade 
autoimmune CD8+ T cell responses against -cell epitopes. PBMCs from HLA-A2+ T1D 
patients (first row) and healthy controls (second row) were assayed against different -cell 
epitopes using either HS-supplemented RPMI containing 0.5 U/ml IL-2 or HS-free AIM-V 
medium containing 0.5 ng/ml IL-7. All values are basal-subtracted, while the basal reactivity 
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is shown as unsubtracted value. Dotted lines indicate the mean + 3SD cut-off for each 
condition. A viral mix stimulus used as further control was positive in all cases. *P<0.04 for 
the difference in basal-subtracted responses. **P<0.01 for the increase in background noise. 
Comparison of cumulative data for all -cell epitope-specific responses in T1D patients gives 
a P<0.001 by Wilcoxon test. The difference in basal reactivities between the two stimulation 
protocols is not statistically significant overall (P=0.44 by Wilcoxon test).
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donor sex age epitope(s) dose
H10N F 48 Flu MP58-66 12.5 nM
H79O F 26 Flu-CMV-EBV 30.0 nM
H15T M 22 Flu MP58-66 25.0 nM
H04N M 33 Flu MP58-66 500  nM
H43H F 70 CMV pp65495-503  0.5  nM
H73N M 27 Flu-CMV-EBV 12.5  nM
H50H M 56 EBV BMLF1280-288 125  nM
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